SI-BONE (2K3) Stock Overview
A medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2K3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SI-BONE, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.70 |
| 52 Week High | US$17.90 |
| 52 Week Low | US$10.60 |
| Beta | 0.69 |
| 1 Month Change | -15.08% |
| 3 Month Change | -36.31% |
| 1 Year Change | -20.15% |
| 3 Year Change | n/a |
| 5 Year Change | -57.20% |
| Change since IPO | -36.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2K3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -7.0% | -5.8% | -3.8% |
| 1Y | -20.1% | -30.9% | -5.1% |
Return vs Industry: 2K3 exceeded the German Medical Equipment industry which returned -29.8% over the past year.
Return vs Market: 2K3 underperformed the German Market which returned -3.9% over the past year.
Price Volatility
| 2K3 volatility | |
|---|---|
| 2K3 Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2K3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2K3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 376 | Laura Francis | si-bone.com |
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.
SI-BONE, Inc. Fundamentals Summary
| 2K3 fundamental statistics | |
|---|---|
| Market cap | €487.91m |
| Earnings (TTM) | -€16.35m |
| Revenue (TTM) | €173.82m |
Is 2K3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2K3 income statement (TTM) | |
|---|---|
| Revenue | US$200.93m |
| Cost of Revenue | US$41.05m |
| Gross Profit | US$159.88m |
| Other Expenses | US$178.78m |
| Earnings | -US$18.90m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 79.57% |
| Net Profit Margin | -9.41% |
| Debt/Equity Ratio | 20.0% |
How did 2K3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/20 09:28 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SI-BONE, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |